Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated
